PRFX Painreform Ltd

USD 0.84 -0.02 -2.077013
Icon

Painreform Ltd (PRFX) Stock Analysis and Price Targets

COMMON STOCK | Drug Manufacturers - Specialty & Generic | NSD
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 0.8391999999999999

-0.02 (-2.08)%

USD 2.17M

0.01M

N/A

N/A

Icon

PRFX

Painreform Ltd (USD)
COMMON STOCK | NSD
USD 0.84
0.00 0
Take a Tour
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 2.17M

N/A

USD 0.84

Painreform Ltd (PRFX) Stock Forecast

N/A

Based on the Painreform Ltd stock forecast from 0 analysts, the average analyst target price for Painreform Ltd is not available over the next 12 months. Painreform Ltd’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Painreform Ltd is Bearish, which is based on 2 positive signals and 6 negative signals. At the last closing, Painreform Ltd’s stock price was USD 0.8391999999999999. Painreform Ltd’s stock price has changed by -5.71% over the past week, -53.38% over the past month and -84.74% over the last year.

No recent analyst target price found for Painreform Ltd
No recent average analyst rating found for Painreform Ltd

Company Overview Painreform Ltd

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly ...Read More

https://www.painreform.com

65 Yigal Alon St., Tel Aviv, Israel, 6744316

7

December

USD

USA

Adjusted Closing Price for Painreform Ltd (PRFX)

Loading...

Unadjusted Closing Price for Painreform Ltd (PRFX)

Loading...

Share Trading Volume for Painreform Ltd Shares

Loading...

Compare Performance of Painreform Ltd Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for PRFX

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Painreform Ltd (Sector: Drug Manufacturers - Specialty & Generic )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NBIX
Neurocrine Biosciences Inc -1.21 (-0.87%) USD14.07B 57.26 37.62

ETFs Containing PRFX

Symbol Name PRFX's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About Painreform Ltd (PRFX) Stock

Stock Target Advisor's fundamental analysis for Painreform Ltd's stock is Bearish.

Unfortunately we do not have enough data on PRFX's stock to indicate if its a good dividend stock.

Unfortunately we do not have enough data on PRFX's stock to indicate what its average analyst target is.

Unfortunately we do not have enough data on PRFX's stock to indicate if its overvalued.

The last closing price of PRFX's stock was USD 0.84.

The most recent market capitalization for PRFX is USD 2.17M.

Unfortunately we do not have enough analyst data on PRFX's stock to indicate whether its price will go up or not.

We can't find any ETFs which contains Painreform Ltd's stock.

As per our most recent records Painreform Ltd has 7 Employees.

Painreform Ltd's registered address is 65 Yigal Alon St., Tel Aviv, Israel, 6744316. You can get more information about it from Painreform Ltd's website at https://www.painreform.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...